RS56874B1 - Glikozaminoglikani koji nisu antikoagulanti koji sadrže ponavljajuću jedinicu disaharida i njihova medicinska upotreba - Google Patents

Glikozaminoglikani koji nisu antikoagulanti koji sadrže ponavljajuću jedinicu disaharida i njihova medicinska upotreba

Info

Publication number
RS56874B1
RS56874B1 RS20180155A RSP20180155A RS56874B1 RS 56874 B1 RS56874 B1 RS 56874B1 RS 20180155 A RS20180155 A RS 20180155A RS P20180155 A RSP20180155 A RS P20180155A RS 56874 B1 RS56874 B1 RS 56874B1
Authority
RS
Serbia
Prior art keywords
heparin
chemically modified
glycosaminoglycan
solution
hours
Prior art date
Application number
RS20180155A
Other languages
English (en)
Serbian (sr)
Inventor
Hans-Peter Ekre
Per-Olov Eriksson
Ulf Lindahl
Erik Holmer
Original Assignee
Dilafor Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48668970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS56874(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dilafor Ab filed Critical Dilafor Ab
Publication of RS56874B1 publication Critical patent/RS56874B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
RS20180155A 2011-12-19 2012-12-19 Glikozaminoglikani koji nisu antikoagulanti koji sadrže ponavljajuću jedinicu disaharida i njihova medicinska upotreba RS56874B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161577223P 2011-12-19 2011-12-19
PCT/SE2012/051433 WO2013095279A1 (en) 2011-12-19 2012-12-19 Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use
EP12858809.2A EP2794665B1 (en) 2011-12-19 2012-12-19 Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use

Publications (1)

Publication Number Publication Date
RS56874B1 true RS56874B1 (sr) 2018-04-30

Family

ID=48668970

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20180155A RS56874B1 (sr) 2011-12-19 2012-12-19 Glikozaminoglikani koji nisu antikoagulanti koji sadrže ponavljajuću jedinicu disaharida i njihova medicinska upotreba

Country Status (28)

Country Link
US (1) US9475888B2 (cg-RX-API-DMAC7.html)
EP (1) EP2794665B1 (cg-RX-API-DMAC7.html)
JP (2) JP6543467B2 (cg-RX-API-DMAC7.html)
KR (1) KR102135485B1 (cg-RX-API-DMAC7.html)
CN (1) CN104144950B (cg-RX-API-DMAC7.html)
AU (1) AU2012354229B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014014454B1 (cg-RX-API-DMAC7.html)
CA (1) CA2856492C (cg-RX-API-DMAC7.html)
CL (1) CL2014001651A1 (cg-RX-API-DMAC7.html)
CO (1) CO7061069A2 (cg-RX-API-DMAC7.html)
CY (1) CY1119899T1 (cg-RX-API-DMAC7.html)
DK (1) DK2794665T3 (cg-RX-API-DMAC7.html)
ES (1) ES2656613T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20180124T1 (cg-RX-API-DMAC7.html)
HU (1) HUE036523T2 (cg-RX-API-DMAC7.html)
IL (1) IL232905A (cg-RX-API-DMAC7.html)
LT (1) LT2794665T (cg-RX-API-DMAC7.html)
ME (1) ME02994B (cg-RX-API-DMAC7.html)
MX (1) MX351104B (cg-RX-API-DMAC7.html)
NO (1) NO2904345T3 (cg-RX-API-DMAC7.html)
PL (1) PL2794665T3 (cg-RX-API-DMAC7.html)
PT (1) PT2794665T (cg-RX-API-DMAC7.html)
RS (1) RS56874B1 (cg-RX-API-DMAC7.html)
RU (1) RU2617764C2 (cg-RX-API-DMAC7.html)
SI (1) SI2794665T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800143T1 (cg-RX-API-DMAC7.html)
WO (1) WO2013095279A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201403640B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
CA2868444A1 (en) * 2012-03-26 2013-10-03 Dilafor Ab Combination treatment comprising sulphated glycosaminoglycans for inducing labor
CA2868479A1 (en) * 2012-03-26 2013-10-03 Dilafor Ab Method for treatment of labor arrest
MX2014013449A (es) * 2012-05-08 2014-12-08 Dilafor Ab Tratamiento de la hemorragia postparto (pph) con heparina modificada quimicamente o sulfato de heparan y un agente uterotonico.
GB2515315A (en) * 2013-06-19 2014-12-24 Dilafor Ab New Processes
CN103788222B (zh) * 2014-01-08 2016-08-31 中国科学院昆明植物研究所 Fuc3S4S取代的低聚糖胺聚糖及其制备方法
CN107001488B (zh) * 2014-04-30 2020-05-12 新加坡科技研究局 硫酸乙酰肝素
CN108424474B (zh) * 2017-02-15 2023-07-25 清华大学 去抗凝肝素衍生物及其用于炎症性肠病的治疗
EP4106765A1 (en) 2020-02-17 2022-12-28 Dilafor AB Tafoxiparin for the treatment of preeclampsia
JP2025514038A (ja) 2022-05-03 2025-05-02 ディラフォール アクチエボラグ タフォキシパリンの新規な医学的使用
EP4272749A1 (en) 2022-05-03 2023-11-08 Dilafor AB New medical use of tafoxiparin
GB202407366D0 (en) * 2024-05-23 2024-07-10 Glycos Biomedical Ltd Preparation of medium molecular weight heparin

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1136620A (en) 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
JPS63246396A (ja) * 1987-03-31 1988-10-13 Shiseido Co Ltd モノクロ−ナル抗体
FR2614026B1 (fr) * 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
SE9002550D0 (sv) 1990-08-01 1990-08-01 Kabivitrum Ab Heparinfragment
SE9003181D0 (sv) 1990-10-04 1990-10-04 Kabivitrum Ab Use of heparin fraction
US5280016A (en) 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5250519A (en) 1991-03-29 1993-10-05 Glycomed Incorporated Non-anticoagulant heparin derivatives
JPH0532703A (ja) * 1991-07-26 1993-02-09 Terumo Corp 低分子量ヘパリン誘導体の製造法
AU5442594A (en) 1992-10-13 1994-05-09 Virginia Commonwealth University Use of non-anticoagulant heparin for treating ischemia/reperfusion injury
US5527785A (en) 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
US5744457A (en) * 1995-03-31 1998-04-28 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
ATE224918T1 (de) * 1995-03-31 2002-10-15 Hamilton Civic Hospitals Res Zusammensetzung zur hemmung der thromboseentstehung
US5993810A (en) 1996-03-15 1999-11-30 Lebovitz; Shamir Israel Method of softening or ripening the cervix of a female mammal using collagenase
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
WO1998016559A1 (fr) 1996-10-15 1998-04-23 Toray Industries, Inc. Agent de maturation des canaux cervicaux
GB9711443D0 (en) 1997-06-03 1997-07-30 Leo Pharm Prod Ltd Chemical suppositions
EP1033375A4 (en) * 1997-11-20 2002-04-24 Ikuo Yamashina MODIFICATION OF LOW MOLECULAR MASS HEPARIN AND REMEDY FOR SKIN Ulcer
US6596705B1 (en) 1998-02-09 2003-07-22 The Regents Of The University Of California Inhibition of L-selectin and P-selection mediated binding using heparin
EP1059304B1 (en) 1998-02-26 2006-04-26 Seikagaku Corporation Novel polysaccharide derivatives, process for the production thereof and medicinal compositions containing the same as the active ingredient
US6028061A (en) 1998-06-18 2000-02-22 Children's Medical Center Corp Angiogenesis inhibitors and use thereof
EP1022289B1 (en) * 1998-07-31 2004-07-07 Seikagaku Corporation Novel glycosaminoglycan and drug compositions containing the same
WO2000013019A1 (en) * 1998-08-26 2000-03-09 The Collaborative Group, Ltd. Receptor for underivatized, aqueous soluble beta-(1,3)-glucan
CZ20014665A3 (cs) * 1999-06-30 2002-05-15 Hamilton Civic Hospitals Research Development, Inc Prostředek s obsahem heparinu se střední molekulovou hmotností
JP4897991B2 (ja) * 1999-07-23 2012-03-14 ラボラトリオス ファルマセウティコス ロビ ソシエダッド アノニマ 超低分子量ヘパリン組成物
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
JP4585072B2 (ja) * 2000-02-29 2010-11-24 扶桑薬品工業株式会社 ヘパリン解重合法、解重合ヘパリン、その誘導体および医薬組成物
DK1319183T3 (da) * 2000-09-12 2009-05-18 Massachusetts Inst Technology Fremgangsmåder og produkter relateret til heparin med lav molekylvægt
SE521676C2 (sv) 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
WO2003088980A1 (en) 2002-04-18 2003-10-30 Embury Stephen H Method and composition for preventing pain in sickle cell patients
US8071569B2 (en) 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
JP2005106694A (ja) * 2003-09-30 2005-04-21 Mochida Pharmaceut Co Ltd 敗血症早期検出及び重篤度評価
EP1582531A1 (en) 2004-03-24 2005-10-05 Aventis Pharma S.A. Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products
US20060040896A1 (en) * 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
US7741311B2 (en) 2005-01-03 2010-06-22 Shaker Mousa Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing
EP1906975A4 (en) 2005-07-22 2010-10-06 Trf Pharma Inc METHOD FOR THE TREATMENT OF SICKLE CELL DISEASE AND CONSEQUENCES OF SICKLE CELL DISEASE
EP1906974A4 (en) * 2005-07-22 2010-06-23 Univ California HEPARINE COMPOSITIONS AND SELECTIN INHIBITION
EP2386858B1 (en) * 2006-04-04 2015-07-15 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
EP2447285A3 (en) * 2006-05-25 2013-01-16 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
WO2009007224A1 (en) * 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Low molecular weight heparin derivatives having neuroprotective activity
MY151984A (en) * 2007-11-02 2014-07-31 Momenta Pharmaceuticals Inc Non-anticoagulant polysaccharide compositions
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8592393B2 (en) * 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
WO2009059284A2 (en) 2007-11-02 2009-05-07 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
WO2009073184A1 (en) 2007-12-03 2009-06-11 Florida State University Research Foundation, Inc. Compositions for inducing labor and associated methods
JP5758797B2 (ja) 2008-04-04 2015-08-05 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション アルキル化半合成グリコサミノグリカンエーテルならびにその製造および使用方法
WO2010111570A1 (en) * 2009-03-27 2010-09-30 E. I. Du Pont De Nemours And Company Polyglycerol aldehydes
CA2758520A1 (en) 2009-04-16 2010-10-21 Momenta Pharmaceuticals, Inc. Methods of assessing activity of a polysaccharide composition
WO2011000032A1 (en) 2009-06-30 2011-01-06 Walter And Eliza Hall Institute Of Medical Research Sulfated polysaccharides having antiplasmodial activity and methods and products for identifying antiplasmodial activity
KR20120060209A (ko) * 2009-07-31 2012-06-11 바이엘 헬스케어 엘엘씨 변형된 인자 ｉｘ 폴리펩티드 및 그의 용도
ES2551388T3 (es) * 2009-12-22 2015-11-18 Lifebond Ltd Modificación de agentes de entrecruzamiento enzimáticos para controlar las propiedades de las matrices entrecruzadas
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
CA2868479A1 (en) 2012-03-26 2013-10-03 Dilafor Ab Method for treatment of labor arrest
CA2868444A1 (en) 2012-03-26 2013-10-03 Dilafor Ab Combination treatment comprising sulphated glycosaminoglycans for inducing labor

Also Published As

Publication number Publication date
KR20140113652A (ko) 2014-09-24
US9475888B2 (en) 2016-10-25
EP2794665B1 (en) 2017-11-22
HUE036523T2 (hu) 2018-07-30
CL2014001651A1 (es) 2014-10-10
RU2014129816A (ru) 2016-02-20
RU2617764C2 (ru) 2017-04-26
HRP20180124T1 (hr) 2018-02-23
EP2794665A1 (en) 2014-10-29
JP6543467B2 (ja) 2019-07-10
IL232905A0 (en) 2014-07-31
JP2018111825A (ja) 2018-07-19
IL232905A (en) 2017-02-28
ME02994B (me) 2018-10-20
SMT201800143T1 (it) 2018-05-02
MX351104B (es) 2017-10-02
CN104144950A (zh) 2014-11-12
BR112014014454A2 (pt) 2017-06-13
EP2794665A4 (en) 2015-08-26
SI2794665T1 (en) 2018-03-30
LT2794665T (lt) 2017-12-27
MX2014007122A (es) 2015-03-05
JP2015500388A (ja) 2015-01-05
WO2013095279A1 (en) 2013-06-27
NO2904345T3 (cg-RX-API-DMAC7.html) 2018-07-21
ZA201403640B (en) 2017-06-28
ES2656613T3 (es) 2018-02-27
CY1119899T1 (el) 2018-06-27
CA2856492A1 (en) 2013-06-27
PT2794665T (pt) 2018-01-24
AU2012354229A1 (en) 2014-06-05
PL2794665T3 (pl) 2018-04-30
US20150011505A1 (en) 2015-01-08
HK1202883A1 (en) 2015-10-09
CO7061069A2 (es) 2014-09-19
KR102135485B1 (ko) 2020-07-17
BR112014014454B1 (pt) 2021-03-09
DK2794665T3 (da) 2018-01-29
CN104144950B (zh) 2017-09-05
AU2012354229B2 (en) 2016-12-01
CA2856492C (en) 2017-01-10

Similar Documents

Publication Publication Date Title
RS56874B1 (sr) Glikozaminoglikani koji nisu antikoagulanti koji sadrže ponavljajuću jedinicu disaharida i njihova medicinska upotreba
EP2794666B1 (en) Use of chemically modified heparin derivates in sickle cell disease
EP0394971A1 (en) Oligosaccharide-containing inhibitors of endothelial cell growth and angiogenesis
EP3010940B1 (en) New processes for the production of chemically-modified heparins
AU671817B2 (en) Sulphated polysaccharides, preparation thereof, pharmaceutical composition and use thereof
JP2020510104A (ja) 内因系テンナーゼ複合体を阻害するオリゴ糖、その製造方法と用途
HK1202883B (en) Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use
HK1220475B (en) New processes for the production of chemically-modified heparins
HK1199893B (en) Use of chemically modified heparin derivates in sickle cell disease
HK1200471B (en) Low anticoagulant heparins